Canada Markets closed

Acer Therapeutics Inc. (ACER)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0200+0.0300 (+1.51%)
At close: 04:00PM EST
Sign in to post a message.
  • a
    aabb
    * ACER + AABB Gold-backed Ethereum tech crypto stock + ALPP added EV battery manuf Mon.
  • H
    H
    With the 10M$ coming in from RELIEF, the company will have cash on hand of 35M$ with no debt. With today's outstanding share count, company will have 2.45$ per share in cash with no debt and FDA approval on ACER-001 during summer of 2022. Now if this isn't a gift from the skies, I don't know what is.
  • H
    H
    Q3 financial results are pretty good actually. Company is very cash rich presently, 10M$ more is coming from Relief, company has no debt, cash-burn is pretty low and ACER-001 will surely get FDA approval by next June with a pipeline of 2 other solid therapeutics. This stock really should be in the 5.00-10.00$ range.
  • H
    H
    Time to load up!
  • A
    Alaa
    Interesting stock. I will start a position next year.. 2 or three months before the fda.
  • H
    H
    This stock is starting to get on my nerves. No interest by the market. And no matter what they do to improve the situation, market clobbers the share price.
  • G
    Gary
    I thought RLF would uplist w an ACER buyout. Obviously not...RLFTY now
  • H
    H
    Somebody needs to wake up this stock. It's been in eternal hibernation!
  • M
    Mark
    I read that ACER is creating a revolutionary cream that is supposed to help tremendously with hemorrhoid's. It is supposed to completely knock out the burning and itching sensations and other discomforts that are associated with chronic hemorrhoid's. If this is the case, it seems that the stock could climb significantly. It will be interesting to see what happens.
  • J
    JP
    $RLFTF conversation
    It was time for me to rebalance. I won't invest in a company where I don't believe in the leadership. Some would say it's too early to judge J Javitt, but there was way too much in the complaint to think that enough of it is likely true. So I went from being 50/50 RLFTF to $NRXP to 83/27 this am. Only holding warrants in NRXP now, no stock.

    Remember the $ACER announcement earlier this week? There's tremendous value in RLFTF even disregarding Aviptadil in the other partnerships and acquisitions they have made when the sp is sub 12 cents.

    I have even more faith in Ram and Jack as business leaders after reading the complaint.
  • F
    Fegami
    At this point, I guess the only positive market catalyst will be getting ACER-001 approved by the FDA...
  • A
    Ammar Alamat
    What's with this stock hitting a new low pre market today?
  • Z
    Zorro
    NEWTON, MA and GENEVA, SWITZERLAND – October 7, 2021 – Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Acer’s patent application No. 17/196,416 for certain claims related to ACER-001 (sodium phenylbutyrate). The allowed patent claims in the application titled, “Palatable Compositions Including Sodium Phenylbutyrate and Uses Thereof,” include pharmaceutical composition claims covering ACER-001’s taste-masked, multi-particulate dosage formulation for oral administration.



    The USPTO issues a patent Notice of Allowance after it determines a patent should be granted upon completion of any outstanding administrative requirements. Acer’s patent is expected to be issued in the fourth quarter of 2021 and expire in 2036. If it receives marketing approval for ACER-001, Acer intends to submit the patent for listing by the U.S. Food and Drug Administration (FDA) in its Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.



    “We are extremely pleased to have received this Notice of Allowance from the USPTO for our proprietary formulation of ACER-001 as we continue to advance its development to potentially treat patients with Urea Cycle Disorders (UCDs), Maple Syrup Urine Disease (MSUD) and other possible indications,” said Jeff Davis, Chief Business Officer at Acer. “This Notice marks another important milestone in our pursuit of possible ACER-001 commercialization while we prepare to bring this treatment to UCDs patients, subject to FDA’s approval of our ACER-001 New Drug Application.”



    Jack Weinstein, Chief Financial Officer and Treasurer of Relief, added, “In parallel to the patent application efforts in the U.S., Acer and Relief are pursuing similar claims in the European Patent Office to cover ACER-001 as we continue to execute on our plan to submit a Marketing Authorization Application for ACER-001 for the treatment of patients with UCDs in Europe in Q2/Q3 2022.”
  • Z
    Zorro
    Analyst Ratings
    H.C. Wainwright reiterated its a Buy rating on Acer Therapeutics Inc. (NASDAQ: ACER), but raised their price target to $55, indicating a potential price increase of 1944.61% for the stock.The consensus rating for Acer Therapeutics Inc. (ACER) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ACER, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.

    What is ACER’s price target for the next 12 months?
    Analysts predict a range of price targets between $10.00 and $10.00, with a median target of $10.00. Taking a look at these predictions, the average price target given by analysts for Acer Therapeutics Inc. (ACER) stock is $10.00.
  • s
    shortsqueezer431
    $ACER Acer Therapeutics Inc. Receives Nasdaq Listing Determination NEW YORK, Oct. 6, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (the “Company”) (NASDAQ: ACER), a healthcare and biotech stock, announced today that on October 6, 2021, Nasdaq notified $ACER that due to the Company’s continued non-compliance with Nasdaq’s annual meeting and filing requirements, as set forth in Nasdaq Listing Rules 5620(a) and 5250(c)(1), respectively, the Company’s securities were subject to delisting unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”).
  • G
    Gary
    Sold all NRX. Looking at ACER or RLF. Tell me your thoughts!! In up to my waist and looking for neck investment! Love you people we are on something that is hidden
  • s
    shortsqueezer431
    Guys need some advice holding 200k shares here at 3.01 bought on the 3 breakout but it didnt go should I hold it?
  • Z
    Zorro
    ACER 8-K sec filing regarding NDA payment from Rlf:

    https://sec.report/Document/0001564590-21-050468/